Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jong Kim

Addiction Medicine Pomona, CA Medical Doctor

NPI 1417477183 CMS profile 8775374

831 E Arrow Hwy, Pomona, CA 91767

Open in the dashboard

General payments

$1,922

80 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jong Kim of Pomona, CA is reported in the CMS Open Payments database as having received $1,922 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 82nd percentile of Addiction Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $365 13
2024 General $320 12
2023 General $324 13
2022 General $702 32
2021 General $212 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jong Kim
  • Addiction Medicine median
  • Middle half of Addiction Medicine
  • National median

In program year 2025, general payments to Jong Kim were reported at $365. Among 306 Addiction Medicine profiles paid that year, the median was $147 and the middle half received between $46 and $381.

Show as a table
Year Jong Kim Addiction Medicine median Middle half National median
2019 $0 $96 $32–$265 $163
2020 $0 $53 $20–$176 $114
2021 $212 $86 $24–$265 $132
2022 $702 $89 $27–$330 $149
2023 $324 $102 $39–$363 $160
2024 $320 $110 $38–$311 $164
2025 $365 $147 $46–$381 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Alkermes, Inc. $589 23 payments
  2. ITI, Inc. $426 21 payments
  3. Indivior Inc. $331 13 payments
  4. AbbVie, Inc. $253 10 payments
  5. Teva Pharmaceuticals USA, Inc. $90 4 payments
  6. Vanda Pharmaceuticals Inc. $88 3 payments
  7. Janssen Pharmaceuticals, Inc $78 3 payments
  8. Otsuka America Pharmaceutical, Inc. $40 2 payments
  9. Gilead Sciences, Inc. $26 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,871 78 payments
  2. Education $50 2 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA $426 21 payments
  2. VIVITROL $413 19 payments
  3. SUBLOCADE $331 13 payments
  4. MAVYRET $253 10 payments
  5. LYBALVI Cns $100 1 payment
  6. LYBALVI Cns $100 1 payment
  7. LYBALVI Cns $100 1 payment
  8. LYBALVI Cns $100 1 payment
  9. FANAPT $88 3 payments
  10. HETLIOZ $88 3 payments
  11. Other $609 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Addiction Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record